Novelion CEO quits Novo Nordisk board due to NASH conflict

May 16 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to "a potential conflict of interest".

by reutersCOMPANYNEWS via Endless Supplies .Biz - News